Emory vs. Vanderbilt FACE-OFF: Novel Therapies Demonstrate Efficacy in Relapsed/Refractory Hematologic Malignancies

home / face-off / emory-vs-vanderbilt-face-off-novel-therapies-demonstrate-efficacy-in-relapsed-refractory

A panel of experts analyzed and discussed phase 2&3 trial findings on efficacy and safety of emerging targeted therapies such as ADCs, bispecific, and CAR-T cells for relapsed/ refractory blood cancers.

Multiple Myeloma and ALL Experts Face Off in Data Analyzing Cilta-Cel and Ponatinib Hydrochloride

EP. 1: Multiple Myeloma and ALL Experts Face Off in Data Analyzing Cilta-Cel and Ponatinib Hydrochloride

ONCOLOGY Staff
February 10th 2024

Vanderbilt University Medical Center and Winship Cancer Institute at Emory University Face Off on recent data in multiple myeloma and acute lymphoblastic leukemia.

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

EP. 2: First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Ashwin Kishtagari, MD;Vivek Govind Patel, MD;Nisha Joseph, MD;Martha Arellano, MD ;Colin Vale, MD
March 4th 2024

Experts provide the first report of results from the Phase 3 PhALLCON trial comparing initial therapy with ponatinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Consolidation Therapy With Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients With B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results From ECOG-ACRIN E1910

EP. 3: Consolidation Therapy With Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients With B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results From ECOG-ACRIN E1910

Ashwin Kishtagari, MD;Vivek Govind Patel, MD;Nisha Joseph, MD;Martha Arellano, MD ;Colin Vale, MD
March 4th 2024

Experts present findings on blinatumomab consolidation therapy from the Phase 3 ECOG-ACRIN E1910 trial in adult patients with newly diagnosed B-lineage acute lymphoblastic leukemia who achieved measurable residual disease-negative remission.

Frontline Combination of Ponatinib and Hyper-CVAD in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: 80-Months Follow-up Results

EP. 4: Frontline Combination of Ponatinib and Hyper-CVAD in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: 80-Months Follow-up Results

Ashwin Kishtagari, MD;Vivek Govind Patel, MD;Nisha Joseph, MD;Martha Arellano, MD ;Colin Vale, MD
March 11th 2024

Experts provide extended follow-up on efficacy and safety outcomes with initial therapy combining ponatinib and hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults (D-ALBA)

EP. 5: Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults (D-ALBA)

Ashwin Kishtagari, MD;Vivek Govind Patel, MD;Nisha Joseph, MD;Martha Arellano, MD ;Colin Vale, MD
March 11th 2024

Experts discuss the Phase 2 D-ALBA trial results examining combination of dasatinib plus blinatumomab as frontline therapy for adults with Philadelphia chromosome-positive B cell acute lymphoblastic leukemia.

Cancer Network Faceoff: Conclusion of the Event and Presentation of Award

EP. 6: Cancer Network Faceoff: Conclusion of the Event and Presentation of Award

Ashwin Kishtagari, MD;Vivek Govind Patel, MD;Nisha Joseph, MD;Martha Arellano, MD ;Colin Vale, MD
March 18th 2024

Final remarks and presentation of awards.